ClearPoint Neuro (CLPT) announced receipt of a Medical Device License from Health Canada for its Neuro Navigation System, further expanding our Drug Delivery ecosystem and global footprint. Covering both ClearPoint MRI-guidance and new iCT-guidance workflows in Canada, the MDL builds on the previously announced therapy delivery product clearance for the SmartFlow Neuro Cannula received in October 2025. This milestone reinforces ClearPoint’s role as a global leader in integrated navigation and therapy delivery solutions and will enable the Company’s biopharma partners to operate Canadian clinical trial and commercial sites using the same platform and standardized workflow already in use in the United States.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLPT:
- Clearpoint Neuro’s IRRAS Acquisition: Integration Risks Threaten Promised Scale and Synergies
- ClearPoint Neuro price target raised to $20 from $18 at B. Riley
- Clearpoint Neuro Charts Aggressive Growth Amid Rising Costs
- ClearPoint Neuro Reports Record 2025 Results, Expands Growth Outlook
- ClearPoint Neuro options imply 11.2% move in share price post-earnings